FDAnews Announces — Biosimilars: Why 2016 Is a Game-Changer Webinar, April 21, 2016

Share Article

In 2016, the FDA will step up its development of a biosimilars regulatory framework and will review multiple proposed biosimilar products. Join Nathan Doty, Associate Director of Biotherapeutics Regulatory Affairs at AbbVie, on April 21 as he covers the issues affecting biosimilars in a 90-minute webinar.

Biosimilars: Why 2016 Is a Game-Changer
April 21, 2016 — 1:30 p.m. – 3:00 p.m. ET
http://www.fdanews.com/biosimilarsgamechanger    

In 2016, the FDA will step up its development of a biosimilars regulatory framework and will review multiple proposed biosimilar products.

Join Nathan Doty, Associate Director of Biotherapeutics Regulatory Affairs at AbbVie, on April 21 as he covers the following issues affecting biosimilars:

  • Potential regulatory actions by FDA on biosimilars issues
  • Analysis of recent FDA regulatory actions surrounding biosimilarity
  • Analysis of the biosimilar market landscape
  • Identification and analysis of scientific, regulatory, and policy issues related to the approval of biosimilars and their role in the market post-approval.

Register today and gain a deep understanding of the current and potential biosimilar regulatory activities.

Meet the Presenter:
Nathan Doty is Associate Director of Biotherapeutics Regulatory Affairs in the Biologics Strategic Development team at AbbVie. Nathan works on biosimilars regulatory issues at the company. Nathan joined AbbVie in Fall 2015 after spending six years working at the Food and Drug Administration — three years in the Office of the Chief Counsel and three years in the Office of the Chief Scientist, within the Office of the Commissioner.    

Who Will Benefit:
Anyone interested in the development of the biosimilars market and the progress toward developing the framework for the regulation of biosimilars including:

  • Pharma and payer general counsel/associate general counsel
  • Pharma regulatory affairs staff
  • Pharma and payer VPs and C-level executives

Webinar Details:
Biosimilars: Why 2016 Is a Game-Changer
April 21, 2016 — 1:30 p.m. – 3:00 p.m. ET
http://www.fdanews.com/biosimilarsgamechanger        

Tuition:
$287 per site

Easy Ways to Register:
Online: http://www.fdanews.com/biosimilarsgamechanger
By phone: 888-838-5578 or 703-538-7600

About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michelle Butler
FDANEWS
+1 (703) 538-7665
Email >
FDAnews
Like >
Visit website